Details of Disease

General Information of Disease (ID: DISKCLM1)

• Disease Name: Erythema multiforme
• Synonyms: febrile mucocutaneous syndrome; Dermatostomatitis, erythema multiforme type; erythema multiforme bullosum; erythema polymorphe, erythema multiforme type; EM; Herpes iris, erythema multiforme type
• Definition: Erythema multiforme (EM) refers to a group ofhypersensitivity disorders characterized by symmetric red, patchy lesions, primarily on the arms and legs. The cause is unknown, but EM frequently occurs in association with herpes simplex virus, suggesting an immunologic process initiated by the virus. In half of the cases, the triggering agents appear to be medications, including anticonvulsants, sulfonamides, nonsteroidal anti-inflammatory drugs, and other antibiotics. In addition, some cases appear to be associated with infectious organisms such as Mycoplasma pneumoniae and many viral agents. Erythema multiforme is the mildest of three skin disorders that are often discussed in relation to each other. It is generally the mildest of the three. More severe is Stevens-Johnson syndrome. The most severe of the three is toxic epidermal necrolysis (TEN).
• Disease Hierarchy:
  DIS9YPUQ: Dermatological disease
  DISKCLM1: Erythema multiforme
• Disease Identifiers:
  MONDO ID: MONDO_0006545
  MESH ID: D004892
  UMLS CUI: C0014742
  MedGen ID: 4527
  SNOMED CT ID: 36715001

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 8 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Betamethasone	DMAHJEF	Approved	Small molecular drug	[1]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[2]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[3]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[4]
Methylprednisolone	DM4BDON	Approved	Small molecular drug	[5]
Prednisolone	DMQ8FR2	Approved	Small molecular drug	[6]
Prednisone	DM2HG4X	Approved	Small molecular drug	[7]
Triamcinolone	DM98IXF	Approved	Small molecular drug	[8]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
MASP2	TTR01E9	Strong	Biomarker	[9]

This Disease Is Related to 6 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
SERPINA5	OTTZXPGD	Limited	Biomarker	[10]
ACADS	OTGFANYQ	Strong	Biomarker	[11]
BFAR	OTTBG0V7	Strong	Biomarker	[12]
DPPA3	OTS7N4Q9	Strong	Genetic Variation	[13]
TBPL1	OT4I143E	Strong	Genetic Variation	[14]
TSPYL2	OTGGW2EF	Strong	Biomarker	[15]

References

• [1] Betamethasone FDA Label
• [2] Cortisone acetate FDA Label
• [3] Dexamethasone FDA Label
• [4] Hydrocortisone FDA Label
• [5] Methylprednisolone FDA Label
• [6] Prednisolone FDA Label
• [7] Prednisone FDA Label
• [8] Triamcinolone FDA Label
• [9] Inherited deficiency of mannan-binding lectin-associated serine protease 2.N Engl J Med. 2003 Aug 7;349(6):554-60. doi: 10.1056/NEJMoa022836.
• [10] Assessment of repeat target lesion percutaneous coronary intervention as a quality measure for public reporting and general quality assessment for PCIs.Catheter Cardiovasc Interv. 2020 Oct 1;96(4):731-740. doi: 10.1002/ccd.28526. Epub 2019 Oct 23.
• [11] Difference in clinical presentations and related angiographic findings among early, late, and very late sirolimus-eluting stent failures requiring target lesion revascularization.Int J Cardiol. 2017 Sep 15;243:116-120. doi: 10.1016/j.ijcard.2017.05.052. Epub 2017 May 13.
• [12] Outcome after new generation single-layer polytetrafluoroethylene-covered stent implantation for the treatment of coronary artery perforation.Catheter Cardiovasc Interv. 2019 Apr 1;93(5):912-920. doi: 10.1002/ccd.27979. Epub 2018 Nov 23.
• [13] Bare Metal Versus Paclitaxel-Eluting Stents for Long Femoropopliteal Lesions: Prospective Cohorts Comparison Using a Propensity Score-Matched Analysis.Ann Vasc Surg. 2017 Aug;43:166-175. doi: 10.1016/j.avsg.2016.10.058. Epub 2017 Mar 11.
• [14] SYNTAX Score and SYNTAX Score II Can Predict the Clinical Outcomes of Patients with Left Main and/or 3-Vessel Disease Undergoing Percutaneous Coronary Intervention in the Contemporary Cobalt-Chromium Everolimus-Eluting Stent Era.Korean Circ J. 2020 Jan;50(1):22-34. doi: 10.4070/kcj.2019.0097. Epub 2019 Sep 30.
• [15] Erythema multiforme-like lesions in primary cutaneous aggressive cytotoxic epidermotropic CD8+ T-cell lymphoma: A diagnostic and therapeutic challenge.J Cutan Pathol. 2017 Oct;44(10):867-873. doi: 10.1111/cup.12995. Epub 2017 Jul 19.